# CJC-1295 / Ipamorelin: Two Receptors, One Somatotroph > CJC-1295 / Ipamorelin: Research Overview — Peptide Pros USA — A briefing on the CJC-1295/ipamorelin research combination: dual-receptor mechanism, the sleep-GH connection, trial findings, and cited safety cautions. **04 / GROWTH HORMONE AXIS RESEARCH** A research combination pairing a long-acting GHRH analog with a selective ghrelin-receptor agonist on the same pituitary cell. ## The short version This page covers the research combination of [CJC-1295](/cjc-1295) and [ipamorelin](/ipamorelin) — two peptides that trigger growth hormone release through two independent receptors on the same pituitary somatotroph cell. CJC-1295 binds the GHRH receptor; ipamorelin binds the separate ghrelin (GHS-R1a) receptor. Because the two pathways are distinct, co-activation is proposed to produce a larger GH pulse than either compound alone. No controlled human trial has ever tested this specific fixed combination — everything said about it is inferred from each peptide's own separate literature, plus general receptor-cross-talk data using related compounds. In research-use communities it carries the same sleep-improvement reputation as its two components individually, plus a cluster of side effects, like water retention and hand tingling, that mirror what each ingredient produces on its own. ## What it is The combination pairs CJC-1295 — a tetra-substituted analog of hGRF(1-29), available in a multi-day albumin-bound "DAC" form or a short-acting "no-DAC" (Modified GRF 1-29) form — with ipamorelin, the selective pentapeptide GHS-R1a agonist Aib-His-D-2-Nal-D-Phe-Lys-NH2. Both are sold only as research chemicals; neither has ever been approved by the FDA for a human indication, and FDA compounding status has shifted repeatedly since 2023. ## How it works CJC-1295 binds the GHRH receptor, a class-B GPCR, raising cAMP via Gs signaling to drive GH synthesis and release. Ipamorelin binds GHS-R1a on the same cells, raising intracellular calcium via a Gq pathway. Because the two receptors signal through different second-messenger systems, co-stimulation is proposed to produce a supra-additive GH pulse — larger than the sum of either agent given alone — with downstream elevation of IGF-1. ## What the research shows There is no published clinical trial of the fixed CJC-1295/ipamorelin combination itself. What exists instead is single-agent and mechanistic evidence read across to the pair. A 2026 meta-analysis of five randomized controlled trials of the GHRH analog tesamorelin found significant reductions in visceral adipose tissue and hepatic fat, increased lean body mass and IGF-1, and no serious adverse events or glucose disruption — the freshest high-quality evidence that GHRH-axis stimulation drives measurable body-composition change with a manageable safety profile [17]. A broader review of growth hormone secretagogues as a class found them generally well tolerated, with the main safety signal being increased blood glucose from reduced insulin sensitivity, and noted that long-term data on cancer incidence and mortality are still needed [18]. On the CJC-1295 side specifically, a single subcutaneous dose in healthy adults raised mean plasma GH 2- to 10-fold for six or more days and IGF-1 1.5- to 3-fold for nine to eleven days [15]. The chemistry that makes that possible — a maleimide linker that covalently binds Cys34 of serum albumin — was defined in a rat study showing roughly a 4-fold increase in GH exposure over two hours compared with unmodified hGRF(1-29), with albumin-bound peptide still detectable in plasma beyond 72 hours [19]. At the receptor level, co-activating cloned GHS and GHRH receptors in transfected cells produced a cAMP response roughly twice that of GHRH-receptor activation alone — a direct mechanistic basis for receptor cross-talk between the ghrelin and GHRH pathways [20]. ## Reported effects, cautions & safety *The following community-reported effects are anecdotal, not clinical evidence, and no dose is implied by any of them.* Deeper, more restorative sleep is the single most-cited benefit of the combination, with users describing falling asleep faster and waking more rested within the first one to two weeks — commonly attributed to layering ipamorelin's independent GH pulse on top of CJC-1295's steadier GHRH-driven background. Faster workout recovery and less next-day soreness are frequently reported, often grouped with other recovery-focused peptides in community write-ups. Gradual fat loss, a leaner appearance, and improved skin, nail, and connective-tissue "feel" are reported occasionally and are heavily bound up with concurrent diet and training. Increased appetite in the hours after injection is frequently reported and traced specifically to ipamorelin's action on the ghrelin receptor. On the adverse side, injection-site redness, itching, or mild swelling is frequently reported and generally described as minor. Water retention and puffiness, facial flushing or a brief head-rush after injecting, tingling or carpal-tunnel-like hand symptoms, and grogginess or a "spacey" feeling are all reported occasionally, echoing what each component produces individually. The cited safety picture is largely class-level rather than combination-specific, because the fixed blend has never been tested as such. Growth hormone is a counter-regulatory hormone that can reduce insulin sensitivity and raise blood glucose, and the secretagogue-class review flags this as the chief metabolic concern of sustained GH-axis stimulation [18]. The same mechanism underlies the fluid retention, carpal-tunnel-type symptoms, and joint discomfort classically associated with growth-hormone excess. Because CJC-1295 (DAC) and ipamorelin act on very different timescales — one lasting days, the other clearing within hours — the combination's actual net GH exposure under any specific protocol has not been characterized in a controlled trial [19]. Elevating GH and IGF-1 chronically also carries the same theoretical, mechanism-based cancer concern discussed on the CJC-1295 and sermorelin pages. Neither compound is FDA-approved, and both are prohibited in sport under WADA Section S2 at all times. ## Where it fits in the Growth Hormone Axis This page is the intersection of the desk: [CJC-1295's](/cjc-1295) GHRH-receptor pathway and [ipamorelin's](/ipamorelin) ghrelin-receptor pathway on the same pituitary cell, with [sermorelin](/sermorelin) as the physiologic reference point both mechanisms ultimately trace back to. See the [comparison page](/compare) for how the evidence for each compound, and the combination, actually stacks up. --- A clinician's-briefing read of the Growth Hormone Axis literature — findings and citations, never a protocol.